XML 28 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cash, Cash Equivalents, Restricted Cash and Marketable Securities
12 Months Ended
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Marketable Securities
4.
Cash, Cash Equivalents, Restricted Cash and Marketable Securities

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:

 

 

 

December 31

 

 

 

2021

 

 

2020

 

 

2019

 

Cash and cash equivalents

 

$

436,189

 

 

$

32,073

 

 

$

39,884

 

Restricted cash

 

 

219

 

 

 

237

 

 

 

216

 

Total cash, cash equivalents and restricted cash shown in the
   consolidated statements of cash flows

 

$

436,408

 

 

$

32,310

 

 

$

40,100

 

Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security to our lease arrangements. See Note 8.

Cash, cash equivalents and marketable securities consist of the following (in thousands):

 

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Estimated
Fair Value

 

December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

6,995

 

 

$

-

 

 

$

-

 

 

$

6,995

 

Money market funds

 

 

429,194

 

 

 

-

 

 

 

-

 

 

 

429,194

 

Total cash and cash equivalents

 

 

436,189

 

 

 

-

 

 

 

-

 

 

 

436,189

 

Marketable securities available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasuries

 

 

4,005

 

 

 

-

 

 

 

(1

)

 

 

4,004

 

U.S. government agency securities

 

 

26,555

 

 

 

-

 

 

 

(7

)

 

 

26,548

 

Corporate debt securities

 

 

79,200

 

 

 

9

 

 

 

-

 

 

 

79,209

 

Total marketable securities available-for-sale

 

 

109,760

 

 

 

9

 

 

 

(8

)

 

 

109,761

 

Total cash, cash equivalents and marketable securities

 

$

545,949

 

 

$

9

 

 

$

(8

)

 

$

545,950

 

December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

7,945

 

 

$

-

 

 

$

-

 

 

$

7,945

 

Money market funds

 

 

23,128

 

 

 

-

 

 

 

-

 

 

 

23,128

 

Corporate debt securities

 

 

1,000

 

 

 

-

 

 

 

-

 

 

 

1,000

 

Total cash and cash equivalents

 

 

32,073

 

 

 

-

 

 

 

-

 

 

 

32,073

 

Marketable securities available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasuries

 

 

32,548

 

 

 

31

 

 

 

-

 

 

 

32,579

 

U.S. government agency securities

 

 

40,313

 

 

 

14

 

 

 

(6

)

 

 

40,321

 

Corporate debt securities

 

 

60,071

 

 

 

3

 

 

 

(11

)

 

 

60,063

 

Total marketable securities available-for-sale

 

 

132,932

 

 

 

48

 

 

 

(17

)

 

 

132,963

 

Total cash, cash equivalents and marketable securities

 

$

165,005

 

 

$

48

 

 

$

(17

)

 

$

165,036

 

 

The maturities of our marketable securities available-for-sale are as follows (in thousands):

 

.

 

December 31, 2021

 

 

 

Amortized
Cost

 

 

Estimated
Fair Value

 

Mature in one year or less

 

$

109,760

 

 

$

109,761

 

Mature after one year through two years

 

 

-

 

 

 

-

 

 

 

$

109,760

 

 

$

109,761

 

 

There were no gross realized gains or losses on investments for each of the year ended December 31, 2021 and 2019. For the year ended December 31, 2020, there were gross realized gains on investments of $0.1 million and no gross realized losses. Realized gains are included in interest income in the consolidated statements of operations. All investments with unrealized losses at December 31, 2021 have been in a loss position for less than twelve months. We do not intend to sell the investments that are in an unrealized loss position before recovery of their amortized cost basis. To date, there have been no declines in fair value that have been identified as other than temporary.